Some great news for inflammatory bowel disease patients with unmet need flew under the radar recently. This field is often overlooked but represents an enormous opportunity. According to the CDC, Crohn’s disease and ulcerative colitis affects over 1 million Americans, but available therapies leave many sufferers untreated. Recently, Johnson & Johnson (NYSE:JNJ) and Celgene (NASDAQ:CELG) each announced positive results from independent programs in both indications that could bring relief to scores of untreated patients in the years ahead.
Help employers find you! Check out all the jobs and post your resume.
